Nuvalent jumps 19% on $350M equity offering

Clinical-stage biopharmaceutical company Nuvalent ( NASDAQ: NUVL ) commenced an underwritten public offering of $350M shares. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Underwriters have a 30-day option to purchase up to an additional 15% of the shares.

Shares of Nuvalent ( NUVL ) jumped 19% to $104 on Monday during pre-market hours of trade. More on Nuvalent Nuvalent: Making Precise Progress In Its Oncology Pipeline Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuvalent Financial information for Nuvalent.